Antagonists of the muscarinic acetylcholine receptor M4

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is a thiazol-2,5-diyl, pyridazin-3,6-diyl, pyrazin-2,5-diyl, pyridin-2,5-diyl, or phthalazin-1,4-diyl, wherein A is optionally substituted with 1-4 substituents independently selected from halo, C1-C4 alkyl, and C1-C4 haloalkyl;
• Q is selected from NRa, O, and CRbRc;
• R1 is selected from —CH═CH—C1-C4 alkyl, —CH═CH-G, C5-C8cycloalkenyl, a 4- to 8-membered monocyclic heterocyclyl, a 6- to 12-membered aryl, and a 5- to 6-membered monocyclic heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S;
• wherein the cycloalkenyl, heterocyclyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, or 3 substituents independently selected from C1-C4 alkyl, halo, cyano, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and —NHCOR′;
• G is a 6- to 12-membered aryl optionally substituted with 1, 2, or 3 substituents independently selected from C1-C4 alkyl, halo, cyano, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and —NHCOR′;
• R′, at each occurrence, is independently C1-C4 alkyl:
• R2 and R3 are independently selected from hydrogen, C1-C4 alkyl, and halo, or R2 and R3 are taken together to form an oxo group;
• R6 is selected from C1-C8 alkyl and —(CRfRg)n—Y1;
• Rf is hydrogen:
• Rg is selected from hydrogen, C1-C4 alkyl and phenyl:
• Y1 is selected from:
• C3-C10-cycloalkyl;
• C5-C10-cycloalkenyl;
• phenyl;
• a 5- to 6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from N, O and S;
• and a 5- to 8-membered heterocyclyl having 1 or 2 heteroatoms independently selected from N, O and S;
• wherein the cycloalkyl, cycloalkenyl, phenyl, heteroaryl and heterocyclyl are unsubstituted or substituted with 1 or 2 substituents independently selected from C1-C4 alkyl, halo, and C1-C4 haloalkyl;
• each Ra, Rb, and Rc is independently selected from hydrogen and C1-C4 alkyl;
• m is 0;
• and
• n is 0 or 1.